title: Discussing breast cancer and hormone replacement therapy with women.
abstract: Although the results of the Women's Health Initiative showed an increased risk of breast cancer in women taking hormone replacement therapy (HRT), the absolute risk is very low. We discuss limitations of the study, questions that remain, and how to discuss the study with women at average risk and high risk for breast cancer.
authors.affiliation: Department of General Internal Medicine, Gault Women's Health and Breast Pavilion, The Cleveland Clinic Foundation, Ohio 44195, USA. baturp@ccf.org
authors.forename: Pelin
authors.initials: P
authors.lastname: Batur
authors.forename: Holly L
authors.initials: HL
authors.lastname: Thacker
authors.forename: Halle C F
authors.initials: HC
authors.lastname: Moore
mesh_terms: D001943:Breast Neoplasms / Q000453:epidemiology / Q000209:etiology*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects; D015233:Models, Statistical; D010353:Patient Education as Topic; D017698:Postmenopause; D045167:Progesterone Congeners / Q000009:adverse effects; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D018570:Risk Assessment
chemical_list: D004966:Estrogens, Conjugated (USP); D045167:Progesterone Congeners; D017258:Medroxyprogesterone Acetate